Full name: Liudan Tu
Current country: China
Membership level: Associate
Type of membership: Member
Number of publications: 6
Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial (2022)
https://pubmed.ncbi.nlm.nih.gov/36091030/
Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial (2022)
https://pubmed.ncbi.nlm.nih.gov/34634368/
A clinical practice guideline for the screening and assessment of enthesitis in patients with spondyloarthritis. (2022)
https://pubmed.ncbi.nlm.nih.gov/36172360/
Active Inflammatory and Chronic Structural Damages of Sacroiliac Joint in Patients With Radiographic Axial Spondyloarthritis and Non-Radiographic Axial Spondyloarthritis. (2021)
https://pubmed.ncbi.nlm.nih.gov/34386008/
Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China. (2020)
https://pubmed.ncbi.nlm.nih.gov/33330342/
Costs and work limitation of patients with ankylosing spondylitis in China (2014)
https://pubmed.ncbi.nlm.nih.gov/25234798/